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 ملخص الرسالة
 
 الإسم بالكامل: عبدالله عمر عبيد باسالم
 عنوان الرسالة:  ) لتطبيقات في مجال التصوير بالرنين المغناطيسي3تصنيع مركبات من الجادلونيوم (
 التخصص:  الكيمياءماجستير العلوم في 
  :لتخرجتاريخ ا  5102أبريل 
 
 
 الجادلونيوم مع مفاعلتها تم وبعد lynizarepiplyra مع مرتبطة edima(sib-APTD( ليجندات أربع صناعة تم
 معدل قياس تم]. O2H4•]O2H)L(dG النوع من تصنيعها تم التي 5 و 4 و 3 و 2 المركبات) III(
 المغناطيسي بالرنين للتصوير تباين معامل وهو® nacsinmO مع ومقارنتها المركبات لهذه) 1R(الاستقرار
 ملاءمتها مدى عن يكشف هذا و سامة، غير المركبات هذه أن الخلوية السمية الدراسات وأشارت. بالاسواق متوفر
 هذه تركيب ةدراس و تحليل وتم. المغناطيسي بالرنين للتصوير تباين معاملات تكون كي والفسيولوجية المحتملة
 لمغناطيسي،ا النووي الرنين العناصر، تحليل ذلك في بما الطيفي، والتحليل التحليلية الأساليب بمساعدة المواد
 .SPX و) SMBAF( السريع النووي القصف ذو الكتلة مطياف الحمراء، تحت الأشعة مطيافية
 
 
 
 
 
 
 
 
 ماجستير العلوم في الكيمياء
  المعادنجامعة الملك فهد للبترول و 
  المملكة العربية السعودية –الظهران 
  5102أبريل 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1. Introduction 
 
In the year 1946, two physicists Felix Bloch and Edward Purcell developed 
the concept of Nuclear Magnetic Resonance (NMR) in liquid and solid [1, 2]. This 
landmark discovery earned them the Noble Prize in 1952. NMR was later applied 
in the medical field for imaging and named Magnetic Resonance Imaging (MRI). 
In 1970, Dr. Raymond Damidian discovered that the key to utilize NMR concept 
for human body imaging is the abundance of water molecules in the body. The first 
human MRI scan was produced in 1975 by Peter Mansfield [3]. To date, 11 contrast 
agents have been approved by the US Food and Drug Administration for 
intravenous use. 
In the early period between 1950s and the 1980s, MRI developed from building on 
previously known NMR techniques to evaluate relaxation of 1H and other nuclei in vivo. 
However, the current MRI uses field gradients to create millimeter thick slices, which allow 
for the detailed acquisition of 2D and 3D images. With the fundamental technology based 
on NMR, MRI uses a radio frequency as the source of excitation during imaging. 
MRI is at present one of the most powerful and efficient non-invasive 
imaging modality in clinical diagnosis. In addition, MRI is considered the safest 
diagnostic technique due to no use of harmful high-energy radiation compared to 
competing radio-diagnostic methods, which use ionizing radiation such as in 
computer tomography (CT) scans or radioactive material in positron emission 
tomography (PET) scans. Currently many different types of contrast inducing 
species have been investigated, ranging from paramagnetic nanoparticles over 
metal complexes of Mn2+, Eu2+ and Gd3+; as well as other lanthanides in the case of 
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saturation transfer contrast agents. Since the approval of Gd-DTPA (Magnevist®) 
for clinical use, lanthanides complexes have been the subject of extensive research 
[4, 5]. The paramagnetic properties Gd-complexes inherit from the presence of 
gadolinium, having seven unpaired electrons, revealing strong relaxation effects [6, 
7]. 
MRI has emerged as an important diagnostic tools due to its exquisite 
anatomical resolution, routinely down to 0.5-1 mm. Now commonplace in the 
clinic, paramagnetic or superparamagnetic metal ions are administered in 40-50% 
of the 7-10 million MR examinations per year [8]. MRI-CA are diagnostic magneto-
pharmaceuticals used to enhance the image contrast by increasing the water proton 
relaxation rate in the body, which allow enhanced tissue contrast and identification 
of lesions (Figure 1). 
 
 
Figure 1: Effect of MR contrast agent 
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With the fundamental technology based on NMR, MRI contrast can be described 
by the two NMR processes of spin relaxation, T1 (longitudinal), and T2 (transverse) 
[9].  
 
1.2. MRI Working Mechanism 
 
The key to MRI is the abundance of water in the human body (Table 1). 
Hydrogen (H1) has a 99.985% natural abundance and very sensitive NMR signal [10]. 
Tissue  Water content 
Kidney 81 % 
Liver 71 % 
Teeth/Bones 10% 
 
Table 1: Water content in different human tissues [11] 
 
The protons of the hydrogen atom is spinning around constantly producing 
a magnetic field. In nature (no applied external magnetic field) protons' magnetic 
moments are aligned in a random manner. Because of that, the net magnetization is 
considered to be zero. By applying an external magnetic field (B0), these magnetic 
moments will align themselves either align or opposite to the direction of B0. There 
tend to be more in the aligned than in the opposite direction of B0 and therefore the 
net magnetization (M0) remains in the direction of B0 (Figure 2) [10]. 
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(a) (b) 
Figure 2: Protons without (a) and (b) with external magnetic field 
 
In reality, the hydrogen atom rotates around the axis of B0 rather than aligning 
with it and this phenomena is known as precession. The frequency needed for 
precession to occur is called Larmor Frequency. It is also the frequency where the 
protons will absorb energy [10]. The following equation describes the precession 
frequency (W0): 
W0 = γ × Bo 
Where γ is the gyromagnetic ratio of H1 in NMR. 
Irradiation at the Larmor frequency using a Rf pulse (B0) will move M0 away from the 
z axis and onto either the x or y axis, where the receiver is situated to measure the 
energy released during relaxation (Figure 3). 
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Figure 3: Representation of net magnetization vector (Mo) a) at equilibrium 
before a Bo is applied (M0 = Mz). b) After a 90° Bo is applied (M0 = Mx). c) After 
a 180° Bo is applied (Mo = M-z). 
 
As the 1H nucleus begin to relax, their frequency of precession can be measured as the 
excess energy is released. 
 
 
1.3. Relaxation Mechanism 
 
The signal-to-noise ratios in MRI rely on the amount of protons present in the 
region of interest and the degree of polarization of the nuclear spin states. When placed 
in a magnetic field, a small population excess of protons will align in the direction of 
the magnetic field and precess at a Larmor resonance frequency related to the strength 
of the magnetic field [12]. When the frequency of the electric field component of the 
incoming radiation is equal to the frequency of the electric field generated by the 
precessing nucleus, energy is absorbed, causing a spin change. The processes by which 
excited nuclei return to their ground state, establishing Boltzmann equilibrium are 
called relaxation processes [13]. Relaxation is calculated in two ways, longitudinal and 
transverse. Longitudinal or spin-lattice relaxation is defined by the time constant T1 and 
occurs in the direction of the applied magnetic field. In this case the spins lose their 
energy by transferring it to the surrounding-the lattice-as thermal energy. Transverse or 
spin-spin relaxation corresponds to vector dephasing in the plane perpendicular to the 
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main magnetic field and is characterized by T2. T1 represents the time required for the 
magnetization vector to be restored to 63% of its original magnitude, and T2 represents 
a 37% decrease in net signal [14]. In addition, T2 is always equal to or shorter than T1. 
Earlier, it was discovered that T1 of tumorous tissues in the human body are longer than 
those of normal tissues (Table 2). 
 
Tissue T1 tumor (s) T1 normal  (s) 
Bone  1.027 0.554 
Breast  1.080 0.367 
Lung  1.110 0.788 
Skin  1.047 0.616 
 
Table 2: T1 values of some tumorous and normal human tissues [11] 
 
1.4. Gadolinium based MR contrast agents 
 
Due to its 7 unpaired 4f electrons, the metal ion Gd3+ (atomic number = 64, MW 
= 157.25) is by far the most paramagnetic metal ion used for MRI. Advances in MRI 
for faster scans and higher resolution have required more rapid pulsing and thus have 
favored T1-weighted imaging and use of contrast enhancers such as Gd
3+. In the 
quantities required for clinical use, free gadolinium ions Gd3+ are extremely toxic. 
Gd(III) is comparable to Ca(II) in size (Gd(III) r = 1.05-1.11 Å, Ca(II) r = 1.00-1.06 
Å), bonding, coordination, and donor atom preference [15]. In addition, when present 
inside the body, gadolinium ion of the complex can be replaced with protons or 
endogenous metal ions such as Cu2+, Zn2+ or Ca2+, during spontaneous dissociation, or 
transmetalation via competitive reactions [16].  
To eliminate the toxicity associated with free Gd(III) ion, many chelates have 
been developed to synthesize Gd(III)-complexes (Figure 4). These highly stable 
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complexation cages have a greater affinity for Gd(III) than other metals commonly 
present in vivo such as Zn(II), Ca(II), or Cu(II) (Fig. 5). Moreover, after complexation, 
renal elimination rises by 550 folds as compared to free Gd(III) metal ion [17]. 
 
Figure 4: Commercially available Gd3+ chelate MR agents. 
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CHAPTER 2 
OBJECTIVES AND WORK PLAN 
 
Following are the objectives of our proposed study: 
(1) The short term objectives of this research are to accomplish the synthesis of Gd 
based complexes (1-5). 
(2) Long term objectives are  
(a) Study the relaxation properties of complexes (1-5) by NMR.  
(b) Application of complexes (1-5) in the MRI. 
 
 
 
Figure 5: Structure of the Gd-complexes (1-5) 
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2.1. Present State of the Problem 
One of the most important properties of contrast agents is the safety of their 
usage. In the quantities required for clinical use, free gadolinium ions Gd3+ are highly 
toxic. In order to reduce its toxicity, gadolinium ion must be transformed into Gd-
complex with appropriate organic chelates or ligands [18,19]. In addition, contrast 
agents should also be able to display an effective impact on selected organs. Gd-DTPA 
(Magnevist®) is a well-established contrast agent in the clinical use for MRI 
applications due to its high relaxivity, high chemical stability and low toxicity. 
However, its passive and nonspeciﬁc distribution in vivo limits its utility in focal lesion 
detection and, in addition, its ionic characteristic leads to some side effects associated 
with its hyperosmolality at clinical dose. Apart from poor sensitivity, the existing 
contrast agents also suffer from fast renal elimination, which extremely shorten the time 
frame for MR imaging [20]. 
In attempts to decrease the side effects and improve the tissue and/or organ-
specificity, we aim to synthesize new ligands derived from suitably substituted 
arylpiperazinyl and diethylene triamine pentaacetic acid (DTPA) and condense them 
with gadolinium to produce gadolinium complexes (1-5) (Figure 5). Based on charge 
law, it is expected that non-ion complexes will be formed from the complexation of 
our proposed ligands with Gd3+ ion, which, in turn, is expected to contribute towards 
low osmotic pressure and organ-specificity [21]. 
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CHAPTER 3 
RESULTS AND DISCUSSION 
 
3.1. Synthesis of the Chelates 
The development of an optimum MRI contrast agent would necessitate 
consideration of high relaxivity, non-cytotoxicity and high water solubility of the 
targeted complexes.  As suggested by earlier report, suitable modification of the ligand 
for instance introduction of polar groups to the alkyl substituents on the amide N-atoms 
of DTPA-bis (amide) can lead to the formation of water soluble Gd-complexes [22]. 
Therefore, we intended to synthesize Gd-complexes with different arylpiperazine 
ligands having different functionalities in the aryl moiety (Figure 6). 
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Figure 6: The Gd (III) attempted to synthesize. 
 
 
 
3.1.1. Synthesis of Complex 1 
The synthesis of complex 1 was envisioned from condensation of ligand 18 
(Scheme 1), bearing nitrile group in the aryl moiety, with GdCl3 or Gd(OAc)3. The 
synthesis of 18, in turn, was commenced as outlined in scheme 1. Condensation of 
benzonitrile 15 [23] with benzoylpiperazine 8 in DMF generated the coupled product 
16 in an excellent yield. Reduction of the nitro group of intermediate 16, using Pd-C or 
Ra-Ni as catalysts was problematic and led to complex mixture of products, which were 
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difficult to resolve by column chromatographic purifications. Hence, the reduction of 
nitro group was conceived via transfer hydrogenation with ammonium formate in 
methanol and Pd-C as catalyst to produce the corresponding intermediates 17 in high 
yield. Finally, reaction of aryl amines 17 with diethylene triamine pentaacetic acid 
dianhydride (DTPAA) [24] in DMF produced the desired ligands 18. We next moved 
on to the synthesis of the final Gd-complex from the reaction of ligand 18. 
Unfortunately, the reaction of ligand 18  either with GdCl3 or Gd(OAc)3 in pyridine 
were unsuccessful, leading to the recovery of 18 only. The nitrile group in aryl ring 
might be playing a role in the decreased reactivity of 18 towards complexation (Scheme 
1). 
 
Scheme 1: The reaction scheme for chelate 1 
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3.1.2. Synthesis of Complexes 2 and 3 
Because of the failure to synthesize Gd-complex from ligand 18, we decided to 
synthesize ligands 26 and 27, which bear methoxy and methoxymethyl substituents in 
the aryl moiety (Scheme 2). Reaction of phenol 19 with appropriate alkyl halide in 
DMF rendered 20 [25] and 21 [26]. Treatment of intermediates 20 and 21 with 
piperazine 8 produced intermediates 22 and 23, respectively (Scheme 2). Reduction of 
the nitro group of intermediates 22 and 23 with ammonium formate in methanol, using 
Pd-C as catalysts generated the corresponding aryl amines 24 and 25 in high yield. 
Condensation of amines 24 and 25 with DTPAA constructed the desired ligands 26 and 
27, respectively. Finally, heating of ligands 26 and 27 with GdCl3 in pyridine produced 
the desired complexes 2 and 3 in good yield (Scheme 2). 
14 
 
Scheme 2: The reaction scheme for chelates 2 and 3. 
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3.1.3. Synthesis of Complexes 4 and 5 
Synthesis of complexes 4 and 5 started with basic hydrolysis of compounds 22 
and 23 to produce compounds 28 and 29, respectively. Michael addition of amine 28 
and 29 with acrylonitrile produced intermediate 30 and 31. The reduction of nitro group 
of 30 and 31 by hydrogenation using Pd-C or Ra-Ni as catalysts was problematic, 
leading to complex mixture of products, which were difficult to resolve. Therefore, the 
reduction of nitro group was conceived via transfer hydrogenation in methanol with 
ammonium formate and Pd-C as catalyst to produce aminonitrile 32 and 33 in high 
yield. DTPAA [24] was condensed with 32 and 33 to construct intermediate 34 and 35, 
which in turn was heated with Gadolinium(III) oxide to produce complex 4 and 5 
respectively (Scheme 3). 
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Scheme 3: The reaction scheme for chelates 4 and 5. 
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3.2. XPS Analysis 
3.2.1. XPS Analysis for Complex 2 
 
Figure 7: XPS survey scan for complex 2. 
 
Figure 8: XPS spectrum of chelate 2. 
2d 
2b 2a
a 
2c 
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(a) C 1s region fitted with 3 peaks. The peak at 284.8 eV is assigned to C-C, the 
peak at 286.0 eV is assigned to C-N and C-O, and the peak at 288.2 eV is assigned to 
C=C and C=O. (b) Gd 4d region fitted with 4 peaks, showing multiplet structure. (c) N 
1s region fitted with one peak. (d) O 1s region fitted with 2 peaks. The peak at 531.4 
eV is assigned to C-O, and the peak at 532.9 eV is assigned to C=O [27]. 
3.2.2. XPS Analysis for Complex 3 
 
Figure 9: XPS survey scan for chelates 3. 
19 
 
 
Figure 10: XPS spectrum of chelate 3. 
 
 
(a) C 1s region fitted with 3 peaks. The peak at 284.8 eV is assigned to C-C, the 
peak at 286.1 eV is assigned to C-N and C-O, and the peak at 288.4 eV is assigned to 
C=C and C=O [4]. (b) Gd 4d region fitted with 4 peaks, showing multiplet structure. 
(c) N 1s region fitted with two peaks. (d) O 1s region fitted with 2 peaks. The peak at 
531.5 eV is assigned to C-O, and the peak at 532.6 eV is assigned to C=O [27]. 
 
 
 
 
 
 
3 a 
3 d 3 c 
3 b 
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3.2.3. XPS Analysis for Complex 4 
 
Figure 11: XPS survey scan for chelates 4. 
 
 
Figure 12: XPS spectrum of chelate 4. 
4 a 
4 d 4 c 
4 b 
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 (a) C 1s region fitted with three peaks (eV) at 284.8 (C-C), 285.8 (C-N, C-O) 
and 287.7 (C=C, C=O). (b) Gd 4d region was fitted with four peaks, showing multiplet 
structure. (c)  N 1s region was fitted with one peak at 399.7 eV. (d)  O 1s region was 
fitted with peaks (eV) at 531.0 (C-O) and 532.7 (C=O) [27]. 
 
3.2.4. XPS Analysis for Complex 5 
 
 
Figure 13: XPS survey scan for chelates 5. 
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Figure 14: XPS spectrum of chelate 5. 
 
(a) C 1s region fitted with three peaks (eV) at 284.8 (C-C), 285.8 (C-N, C-O) 
and 287.7 (C=C, C=O). (b) Gd 4d region was fitted with four peaks, showing multiplet 
structure. (c)  N 1s region was fitted with one peak at 399.7 eV. (d)  O 1s region was 
fitted with peaks (eV) at 531.0 (C-O) and 532.7 (C=O) [27]. 
 
3.3. T1 Measurements in MRI 
Relaxivity measurements of (2-5): Longituditional relaxation (T1) 
measurements of complexes (2-5) were performed in water at 298K on 3 Tesla MRI 
machine. The magnetic resonance images were taken at 17 different repetition time 
(TR) values, ranging from 20 to 1500 msec and T1 values were obtained from non-
linear least-square fit measured at each TI values. Relaxvities (R1) were calculated as 
an inverse of relaxation times per mM [28]. 
5 a 
5 d 5 c 
5 b 
23 
 
CA 
T1 
(msec) 
R1 
(mM-1sec-1) 
1 415.72±2.32 2.40 
2 360.93±1.56 2.77 
3 293.51±1.21 3.40 
4 235.67±1.01 4.24 
Omniscan®a 312.50 3.2 
 
Table 3:T1 of chelates (2-5). 
 
3.4. Cytotoxicity Studies 
Compounds were evaluated for their toxicity using 3T3 fibroblast cell line by MTT 
cytotoxicity assay, where all tested compounds were found to be nontoxic. The half 
maximal inhibitory concentration (IC50) is a measure of how effective a substance is in 
suppressing a specific biological or biochemical function. 
Compound 
Cytotoxicity on 3T3 fibroblast cells 
(IC50 μg/mL) 
2 >50 
3 >50 
4 >50 
5 >50 
Cyclohexamide 0.13 ± 0.02 
 
Table 4: cytotoxicity data of chelate (2-5) 
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CHAPTER 4 
EXPERIMENTAL PART 
 
4.1. Materials Used 
 
Chemicals were purchased from commercial sources, and they were used 
without any further purification unless otherwise specified. All solvents were of reagent 
grade. Specially dried (anhydrous) solvents were used where necessary. Glassware for 
moisture-sensitive reactions were oven dried at 120-140 °C for at least three hours and 
cooled in a desiccators prior to use. Some of the reactions were run in an inert 
atmosphere of nitrogen or argon as stated.  
Purification of the products was carried out either by recrystallization or by flash 
column chromatography. The column was packed with silica gel 100 from Fluka 
Chemie AG (Buchs, Switzerland). 
 
4.2. Product Identification 
The following techniques were used to identify our products: 
I. NMR Spectroscopy: 1H NMR and 13C NMR spectra were recorded on JEOL 
Lambda 500 MHz spectrometer. Chemical shifts were reported in ppm (δ) relative 
to tetramethyl silane (TMS) by using (CDCl3), (DMSO) or D2O as deuterated 
solvents. Multiplicities were reported as singlet (s), doublet (d), triplet (t), quartet 
(q) or multiplet (m), and coupling constants (J) were reported in hertz (Hz). 
II. IR Spectroscopy: IR Spectra were recorded on a NicoletTM 6700 FT-IR 
spectrometer from a thermo-electron by making KBr pallets for solids and using 
NaCl disks for liquids. 
25 
 
III. Elemental Analyzer "CHN": Elemental analysis was carried out on a 
EuroVector Elemental Analyzer Model EA3000. 
IV. FABMS: Mass was determined by using JEOL JMS-600H. 
V. Thin Layer Chromatography: TLC was frequently used to monitor reactions 
and to give qualitative determination of sample purity. TLC analyses were 
performed on silica gel Merck 60 F254 plates, and spots were visualized under a 
spectroline UV lamp. Visualization was improved by using iodine chamber. 
 
4.3. Synthesis of Gd-Complexes 
4.3.1. Synthesis of phenyl(piperazin-1-yl)methanone (8) 
N
H
N
Bz
8  
This compound was synthesized as per the literature procedures [29]. In a flask 
(1.36g, 20 mmol) of imidazole was dissolved in (50 ml) of DCM. (1.40g, 10 mmol) of 
benzoyl chloride 6 was added to this solution and left to stir at 0 oC for two hours. After 
that a white precipitate of imidazole hydrochloride was filtered off. The organic layer 
was concentrated in rotavap and reconstituted in (25 ml) ethanol. In another flask, 
(2.06g, 13 mmol) of piperazine dihydrochloride was dissolved in (25 ml) of water. The 
ethanolic solution was slowly added over a 10 minutes period to the water solution and 
left to stir at room temperature for six hours. The solution was reduced to 1/4 of its 
original volume using rotavap. The remaining solution was washed with DCM (4x25 
ml) to remove the dialcylated product. (10 ml) of concentrated NaOH was added to the 
aqueous layer and then washed with (4x25 ml) of DCM. Finally, the organic layer was 
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dried over anhydrous CaSO4 and dried to afford a pale yellow liquid 8 (1.66g, 67.3%). 
IR (Film): 3522, 3297, 2999, 2914, 2822, 2744, 2361, 1966, 1636, 1577, 1525, 1495, 
1433, 1365, 1162, 1140, 1062, 1016, 925, 867, 820, 787, 733, 708, 665, 635, 592, 545 
cm-1. 1H NMR (500 MHz, CDCl3) δ: 1.99 (br s, 1H), 2.77 (d, 4H, J= 69.55 Hz), 3.37 
(br s, 2H), 3.73 (br s, 2H), 7.39 (m, 5H). 13C NMR (125 MHz, CDCl3) δ: 42.92, 45.60, 
49.65, 126.64, 128.14, 129.26, 135.60, 170.07. 
 
4.3.2. Synthesis of 2-(bis(2-(2,6-dioxomorpholino)ethyl)amino)acetic 
acid (10) 
N
NN
HO
O
O O
O
O
O
O
10
 
This compound was synthesized as per the literature procedures [30] the 
synthesis is as follows. 9 (10.00 g, 25.42 mmol) was suspended in pyridine (15 ml). 
After that acetic anhydride (10.80 ml, 114.40 mmol) was added and left stirring at 55 
oC for 48 hours. At the end of the reaction, the color of the solvents will change from 
colorless to brown. The product was filtered off and then washed with DCM until a 
uniform color was seen. 10 was obtained as a creamy powder (7.68 g, 84.57%). 
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4.3.3. Synthesis of 4-bromo-2-nitrobenzonitrile (15) 
 
CN
Br
NO2
15  
 
This compound was synthesized as per the literature procedures [23]. To a cold 
solution of trifluoroacetic acid (18 mL) at 0 °C was added compound 15a (4.5 g, 22.8 
mmol). After being stirred for 10 minutes, a solution of 33% hydrogen peroxide (7 mL, 
67.8 mmol) was added and the mixture was stirred at room temperature for 0.5 h 
followed by stirring at 50 °C for 2 h. The mixture was poured into ice water and the 
solid obtained was filtered and washed with cold water to afford 3.64 g (70%) of 
compound 15 as an off-white solid, m.p. 84-85 °C; IR (KBr) ν max. cm-1: 3042 (Ar-H), 
2252 (CN), 1520, 1412 (C=C). 1H NMR (500 MHz, DMSO-d6) δ = 8.15 (dd, 1H, J = 
2.4, 8.5 Hz, H-5); 8.25 (d, 1H, J = 8.4 Hz, H-6); 8.46 (d, 1H, J = 2.4 Hz, H-3); 13C 
NMR (125.7 MHz, DMSO-d6) δ = 108.88 (C-1), 114.54 (CN), 127.43 (C-3), 128.75 
(C-4), 137.57 (C-5/C-6), 138.10 (C-5/C-6), 147.59 (C-2). Calculated (%) for 
C7H3BrN2O2 (225.94); C: 37.03, H: 1.33, N: 12.34, found (%); C: 37.00, H: 1.37, N: 
12.27. 
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4.3.4. Synthesis of 4-(4-benzoylpiperazin-1-yl)-2-nitrobenzonitrile 
(16) 
CN
NO2
N
N
Bz
16  
To a solution of amine 8 (1.82 g, 9.56 mmol) in DMF (20 mL) at 0 oC was added 
K2CO3 (3.61 g, 26.13 mmol) followed by the addition of compound 15 (1.96 g, 8.67 
mmol) and the reaction was stirred overnight at 60 oC. After completion of the reaction 
(TLC analysis), the mixture was cooled to room temperature and diluted with ethyl 
acetate (75 ml). The solution was washed with H2O (30 mL x 3), brine (20 ml x 2) and 
the organic layer was separated, dried over Na2SO4 and evaporated under vacuum to 
afford the title compound 5 as as light yellow amorphous solid (2.16 g, 74%), m.p. 196-
197 oC. IR (KBr): 3063, 2999, 2929, 2233, 1670, 1622, 1596, 1578, 1457, 1430, 1389, 
1341, 1294, 1249, 1155, 1094, 1072 cm-1. 1H-NMR (500 MHz, CDCl3): δ 3.47 (br. s, 
4H, -CH2NCH2-), 3.79 (br. s, 4H, -CH2NCH2-), 6.99 (dd, 1H, J = 2.6, 9.4 Hz, Ar-H), 
7.14 (d, 1H, J = 2.7 Hz, Ar-H), 7.40-7.48 (m, 5H, Ar-H), 8.19 (d, 1H, J = 9.5 Hz, Ar-
H). 13C-NMR (125 MHz, CDCl3): δ 46.44, 46.84, 110.05, 115.66, 118.89, 126.93, 
127.10, 127.79, 128.67, 130.33, 134.69, 137.79, 153.10, 170.61. Anal. Calcd for 
C18H16N4O3: C, 64.28; H, 4.79; and N, 16.66. Found: C, 64.22; H, 4.84; and N, 16.60. 
 
. 
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4.3.5. Synthesis of 2-Amino-4-(4-benzoylpiperazin-1-yl)benzonitrile 
(17) 
CN
NH2
N
N
Bz
17  
 
To a solution of compound 16 (2.93 g, 7.12 mmol) in anhydrous methanol (50 
mL) was sequentially added Pd-C (10% wet basis, 0.25 g) and ammonium formate 
(2.25 g, 35.63 mmol) and the mixture was refluxed for 3 hours. The reaction mixture 
was filtered through a pad of celite and the filtrate was concentrated under vacuum. 
Column chromatography of the dark purple oily material eluting with MeOH:CH2Cl2 
(1:9) afforded the title compound 6 as a light brown thick oil (1.77 g, 81%). IR (KBr): 
3455, 3348, 3060, 2916, 2821, 2213, 1669, 1631, 1577, 1505, 1437, 1388, 1313, 1284, 
1241, 1158, 1095 cm-1. 1H-NMR (500 MHz, CDCl3): δ 2.86 (br. s, 4H, -CH2NCH2-), 
3.49 (br. s, 2H, -CH2N), 3.83 (br. s, 2H, -CH2N), 4.32 (br. s, 2H, -NH2), 6.61 (d, 1H, J 
= 8.6 Hz, Ar-H), 6.79 (d, 1H, J = 2.4, Ar-H), 6.94 (dd, 1H, J = 2.4, 8.6 Hz, Ar-H), 
7.34(m, 5H, Ar-H). 13C-NMR (125 MHz, CDCl3): δ 41.81, 47.34, 50.62, 53.32, 95.69, 
116.52, 117.54, 119.43, 125.63, 126.76, 128.28, 129.61, 135.19, 142.64, 144.71, 
170.09. Anal. Calcd for C18H18N4O: C, 70.57; H, 5.92; and N, 18.29. Found: C, 70.50; 
H, 5.97; and N, 18.22. 
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4.3.6. Synthesis of 2,2'-(2,2'-(carboxymethylazanediyl)bis(ethane-2,1-
diyl)bis((2-(5-(4-benzoylpiperazin-1-yl)-2-cyanophenylamino)-
2-oxoethyl)azanediyl))diacetic acid (18) 
N
NN
HO
O
OH HO
O
O
O
O
NH NH
CN
N
N
Bz
NC
N
N
Bz 18  
 
To a solution of DTPAA (0.175 g, 0.49 mmol) in DMF (10 mL) was added 
compound 6 (0.30 g, 0.98 mmol) and the reaction mixture was stirred at 80 oC for 16 
hours. The mixture was cooled to ̴ 40 oC, filtered through a pad of silica gel and the 
filtrate was concentrated under reduced pressure. The residue was added drop wise to 
cold acetone (50 ml) and the precipitated product was filtered by suction, dried under 
reduced pressure to afford compound 7 as an off-white powder (0.31 g, 65%), m.p. 158-
160 oC. IR (KBr): 3467, 2917, 2509, 2362, 2228, 1690, 1627, 1517, 1437, 1389, 1284, 
1241, 1160, 1048, 1011, 962, 829, 788, 708, 633, 559, 493, 424 cm-1. 1H-NMR (500 
MHz, DMSO-d6): δ 2.90-3.20 (m, 10H), 3.43-3.72 (m, 24H), 7.22-7.26 (m, 4H, Ar-H), 
7.45-7.49 (m, 14H, Ar-H), 10.03 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ 41.21, 
48.05, 51.13, 52.46, 55.07, 57.89, 107.65, 117.08, 118.42, 121.01, 125.85, 127.02, 
128.49, 129.68, 121.57, 135.72, 147.91, 169.10, 170.01, 172.63. Anal. Calcd for 
C50H55N11O10 ● H2O: C, 60.78; H, 5.81; and N, 15.59. Found: C, 60.72; H, 5.85; and N, 
15.52. FAB-MS (m/z): calcd for C50H55N11O10, 969.4 ([MH]
+). Found: 969.3 ([MH]+).  
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4.3.7. Synthesis of 4-fluoro-2-methoxy-1-nitrobenzene (20) 
 
20
NO2
F
OCH3
 
19 (1.00 g, 6.4 mmol) was dissolved in DMF (15 ml) and stirred at 0 oC for 5 
minutes and then K2CO3 (1.33 g, 9.6 mmol). The suspension left to stir at 0 
oC for 15 
minutes. After that CH3I (0.6 ml, 9.6 mmol) was added and left stirring at 40 
oC 
overnight. TLC was used to check the completion of the reaction. The reaction was 
cooled and ether (25 ml) was added and the solution was transferred to a separation 
funnel. The solution was washed with H2O (20 ml x 3), 10% HCl (10 ml x 1) and brine 
(10 ml x 1). The organic layer was collected, dried over CaSO4 and dried under vacuum 
to afford 20 as yellowish white solid (1.08 g, 98%). MP: 41-43 oC. IR (KBr): 2442, 
1890, 1626, 1524, 1445, 1350, 1284, 1192, 1162, 1136, 1090, 1020, 954, 841, 748, 688, 
631, 577, 532 cm-1. 1H NMR (500 MHz, CDCl3) δ: 3.95 (s, 3H), 6.73 (m, 1H), 6.75 
(dd, 1H, J1= 12.82 Hz, J2 = 6.41 Hz), 7.96 (dd, 1H, J1 = 10.07 Hz, J2 = 5.04). 13C NMR 
(125 MHz, CDCl3) δ: 65.76, 101.56, 107.52, 128.23, 155.37, 164.91, 166.34. 
 
4.3.8. Synthesis of 4-fluoro-2-(methoxymethoxy)-1-nitrobenzene (21) 
21
NO2
F
OMOM
 
 
19 (2.00 g, 12.7 mmol) was dissolved in DMF (30 ml) and stirred at 0 oC for 5 
minutes and then K2CO3 (2.63 g, 19.05 mmol). The suspension left to stir at 0 
oC for 
15 minutes. After that MOMCl (1.00 ml, 12.7 mmol) was added and left stirring at 40 
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oC overnight. TLC was used to check the completion of the reaction. The reaction was 
cooled and ether (75 ml) was added and the solution was transferred to a separation 
funnel. The solution was washed with H2O (30 ml x 3), 10% HCl (20 ml x 1) and brine 
(20 ml x 1). The organic layer was collected, dried over CaSO4 and dried under vacuum 
to afford 21 as yellow liquid (2.14 g, 83.8%). IR (Film): 3091, 2937, 2837, 2361, 1676, 
1621, 1591, 1529, 1490, 1397, 1352, 1280, 1215, 1158, 1079, 994, 936, 846, 822, 752, 
660, 606 cm-1. 1H NMR (500 MHz, CDCl3) δ: 3.53 (s, 3H), 5.30 (s, 2H), 6.80 (m, 1H), 
7.08 (dd, 1H, J1= 9.46 Hz, J2= 4.73 Hz), 7.92 (m, 1H). 13C NMR (125 MHz, CDCl3) 
δ: 56.70, 95.29, 104.55, 108.57, 127.47, 136.66, 152.43, 164.20, 166.23. 
 
4.3.9. Synthesis of (4-(3-methoxy-4-nitrophenyl)piperazin-1-yl) 
(phenyl)methanone (22) 
NO2
OCH3
N
N
Bz
22  
Following the same procedure adopted for the synthesis of 16, the reaction of 
amine 8 with compound 20 (1.49 g, 8.71 mmol) afforded the title compound 22 as as 
bright yellow amorphous solid (2.91 g, 98%), m.p. 185-187 oC. IR (KBr): 3021, 1627, 
1575, 1488, 1461, 1436, 1383, 1336, 1314, 1245, 1156, 1102, 1080 cm-1. 1H-NMR (500 
MHz, CDCl3): δ 3.40-3.50 (br. s, 4H, -CH2NCH2-), 3.94 (s, 3H, -OCH3), 4.64 (br. s, 
4H, -CH2NCH2-), 6.33 (d, 1H, J = 2.4 Hz, Ar-H), 6.43 (dd, 1H, J = 2.4, 9.1 Hz, Ar-H), 
7.45 (m, 5H, Ar-H), 8.00 (d, 1H, J = 9.1 Hz, Ar-H). 13C-NMR (125 MHz, CDCl3): δ 
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47.01, 56.23, 97.62, 105.75, 127.08, 128.61, 128.74, 130.16, 134.97, 155.23, 156.07, 
170.55. Anal. Calcd for C18H19N3O4: C, 63.33; H, 5.61; and N, 12.31. Found: C, 63.26; 
H, 5.66; and N, 12.26. 
  
4.3.10. Synthesis of (4-(3-(methoxymethoxy)-4-nitrophenyl) 
piperazin-1-yl)(phenyl)methanone (23) 
NO2
OMOM
N
N
Bz
23  
 
Following the same procedure adopted for the synthesis of 16, the reaction of 
amine 8 with compound 21 (4.10 g, 21.39 mmol) afforded the title compound 23 as 
light yellow solid (7.34 g, 97%), m.p. 189-190 oC. IR (KBr): 3032, 1675, 1620, 1575, 
1490, 1461, 1436, 1383, 1336, 1314, 1249, 1150, 1102, 1078, 1035 cm-1. 1H NMR (500 
MHz, CDCl3): δ 3.31-3.33 (br. s, 4H, -CH2NCH2-), 3.45 (s, 3H, -OCH3), 3.85 (br. s, 
4H, -CH2NCH2-), 5.21 (s, 2H, -OCH2O-), 6.42 (dd, 1H, J = 2.4, 9.4 Hz, Ar-H), 6.56 (d, 
1H, J = 2.4, Ar-H), 7.36 (m, 5H, Ar-H), 7.85 (d, 1H, J = 9.3 Hz, Ar-H). 13C NMR (125 
MHz, CDCl3): δ 46.99, 56.53, 67.02, 95.38, 101.37, 106.83, 126.91, 128.24, 128.42, 
129.92, 134.87, 153.48, 154.77, 162.33, 170.28. Anal. Calcd for C19H21N3O5: C, 61.45; 
H, 5.70; and N, 11.31. Found: C, 61.41; H, 5.75; and N, 11.25. 
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4.3.11. Synthesis of (4-(4-Amino-3-methoxyphenyl)piperazin-1-
yl)(phenyl)methanone (24) 
NH2
OCH3
N
N
Bz
24  
Following the same procedure adopted for the synthesis of 17, the reduction of 
the nitro group of compound 22 (2.43 g, 7.12 mmol) afforded compound 24 as a dark 
brown thick oil (1.84 g, 83%). IR (KBr): 3447, 3346, 3058, 2917, 1673, 1629, 1518, 
1438, 1386, 1323, 1282, 1245, 1197, 1170, 1093, 1034, 1015 cm-1. 1H-NMR (500 MHz, 
CDCl3): δ 2.92 (br. s, 2H, -CH2N), 3.07 (br. s, 2H, -CH2N), 3.53 (br. s, 2H, -CH2N), 
3.79 (s, 3H, -OCH3), 3.89 (br. s, 2H, -CH2N), 6.37 (dd, 1H, J = 2.4, 8.2 Hz, Ar-H), 6.47 
(d, 1H, J = 2.4, Ar-H), 6.59 (d, 1H, J = 8.3, Ar-H), 7.38 (m, 5H, Ar-H). 13C-NMR (125 
MHz, CDCl3): δ 42.23, 47.80, 51.59, 51.81, 53.36, 55.35, 102.74, 109.98, 115.21, 
126.96, 128.39, 129.64, 130.85, 135.56, 144.25, 147.85, 170.24. Anal. Calcd for 
C18H21N3O2: C, 69.43; H, 6.80; and N, 13.49. Found: C, 69.36; H, 6.87; and N, 13.42. 
 
 
 
 
 
 
35 
 
4.3.12. Synthesis of (4-(4-amino-3-(methoxymethoxy)phenyl) 
piperazin-1-yl)(phenyl)methanone (25) 
NH2
OCH2OCH3
N
N
Bz
25  
Following the same procedure adopted for the synthesis of 17, the reduction of 
the nitro group of compound 23 (1.53 g, 4.12 mmol) afforded compound 25 as a dark 
purple thick oil (1.13 g, 80%). IR (KBr): 3447, 3352, 3010, 2953, 1671, 1628, 1516, 
1436, 1366, 1325, 1284, 1241, 1214, 1150, 1074 cm-1. 1H-NMR (500 MHz, CDCl3): δ 
2.92 (br. s, 2H, -CH2N), 3.08 (br. s, 2H, -CH2N), 3.46-3.44 (m, 5H, -OCH3, -CH2N), 
3.53 (br. s, 2H, -CH2N), 3.89 (br. s, 2H, -NH2), 5.13 (s, 2H, -OCH2O-), 6.44 (dd, 1H, J 
= 2.4, 8.3 Hz, Ar-H), 6.61 (d, 1H, J = 8.4, Ar-H), 6.72 (d, 1H, J = 2.4 Hz, Ar-H), 7.38 
(m, 5H, Ar-H). 13C-NMR (125 MHz, CDCl3): δ 42.18, 47.69, 51.40, 55.99, 95.25, 
106.35, 111.64, 115.81, 126.95, 128.37, 129.63, 131.22, 135.53, 144.12, 145.52, 
170.23. Anal. Calcd for C19H23N3O3: C, 66.84; H, 6.79; and N, 12.31. Found: C, 66.77; 
H, 6.86; and N, 12.24. 
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4.3.13. Synthesis of 2,2'-(2,2'-(carboxymethylazanediyl) 
bis(ethane-2,1-diyl)bis((2-(4-(4-benzoylpiperazin-1-yl)-2-
methoxyphenylamino)-2-oxoethyl)azanediyl))-diacetic acid (26) 
N
NN
HO
O
OH HO
O
O
O
O
NH NH
N N
OCH3OCH3
N N
Bz Bz
26  
 
Following the same procedure adopted for the synthesis of 18, condensation of 
compound 24 (0.89 g, 2.86 mmol) with DTPAA afforded compound 26 as a white 
powder (0.87 g, 62%), m.p 151-153 oC. IR (KBr): 3453, 3021, 2924, 1728, 1629, 1531, 
1441, 1389, 1285, 1201, 1156, 1089, 1031, 1013 cm-1. 1H-NMR (500 MHz, DMSO-
d6): δ 2.71 (br. s, 4H), 2.96-3.30 (m, 6H), 3.34-3.73 (m, 24H), 3.75 (s, 6H, -OCH3), 
6.40 (dd, 2H, J = 2.4, 8.2 Hz, Ar-H), 6.60 (d, 2H, J = 2.4, Ar-H), 7.44 (m, 10H, Ar-H), 
7.93 (d, 2H, J = 8.2 Hz, Ar-H), 9.34 (s, 2H). 13C-NMR (125 MHz, DMSO-d6): δ 30.97, 
49.39, 52.54, 55.17, 55.70, 56.01, 100.77, 107.72, 119.85, 121.68, 127.26, 128.82, 
130.01, 135.91, 168.99, 169.59, 172.70. Anal. Calcd for C50H61N9O12 ● H2O: C, 60.17; 
H, 6.36; and N, 12.63. Found: C, 60.11; H, 6.42; and N, 12.57. FAB-MS (m/z): calcd 
for C50H61N9O12, 979.44 ([MH]
+). Found: 979.3 ([MH]+).  
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4.3.14. Synthesis of 2,2'-(2,2'-(carboxymethylazanediyl) 
bis(ethane-2,1-diyl)bis((2-(4-(4-benzoylpiperazin-1-yl)-2-
(methoxymethoxy)phenylamino)-2-oxoethyl)azanediyl))diacetic 
acid (27) 
 
N
NN
HO
O
OH HO
O
O
O
O
NH NH
N N
OCH2OCH3
OCH2OCH3
N N
Bz Bz
26
27  
Following the same procedure adopted for the synthesis of 18, condensation of 
compound 25 (0.26 g, 0.76 mmol) with DTPAA afforded compound 27 as a white 
powder (0.15 g, 38%), m.p. 165-167 oC. IR (KBr): 3452, 3021, 2929, 1722, 1626, 1536, 
1443, 1389, 1285, 1201, 1153, 1089, 1031, 1015 cm-1. 1H-NMR (500 MHz, DMSO-
d6): δ 2.74-2.82 (br. s, 4H), 2.95-3.13 (m, 6H), 3.29-3.70 (m, 24H), 3.73 (s, 6H, -OCH3), 
5.19 (s, 4H, -OCH2O-), 6.54 (dd, 2H, J = 2.6, 8.6 Hz, Ar-H), 6.72 (d, 2H, J = 2.5, Ar-
H), 7.44 (m, 10H, Ar-H), 7.92 (d, 2H, J = 8.5 Hz, Ar-H), 9.50 (s, 2H). 13C-NMR (125 
MHz, DMSO-d6): δ 49.09, 52.36, 55.89, 59.00, 94.54, 103.68, 109.01, 120.84, 126.99, 
128.45, 129.59, 135.81, 147.10, 169.04. Anal. Calcd for C52H65N9O14 ● H2O: C, 59.02; 
H, 6.38; and N, 11.91. Found: C, 58.96; H, 6.44; and N, 11.85. FAB-MS (m/z): calcd 
for C52H65N9O14, 1039.47 ([MH]
+). Found: 1039.3 ([MH]+). 
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4.3.15. Synthesis of complex (2) 
 
O
O
N
N
O
O
HN
N
O
O O
NH
O
Gd
H
O H
N N
N N
Bz Bz
OCH3H3CO
2  
To a solution of compound 26 (0.30 g, 0.31 mmol) in pyridine (15 mL) was 
added GdCl3 ● 6H2O (0.11 g, 0.30 mmol) and the reaction mixture was stirred at 90 
oC 
for 8 hours. The mixture was filtered through a pad of celite while hot and the filtrate 
was concentrated under reduced pressure. The residue was added drop wise to cold 
acetone (25 ml) and the precipitated product was filtered, dried under reduced pressure 
to afford compound 1 as a white amorphous solid (0.25 g, 70%), m.p. > 300 oC. IR 
(KBr): 3426, 3036, 2973, 1641, 1438, 1324, 1251, 1202, 1153, 1092, 1007 cm-1. Anal. 
Calcd for C50H58GdN9O12 ● 4H2O: C, 49.78; H, 5.51; and N, 10.45. Found: C, 49.71; H, 
5.57; and N, 10.38. FAB-MS (m/z): calcd for C50H58GdN9O12, 1134.34 ([MH]
+). 
Found: 1134.3 ([MH]+). 
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4.3.16. Synthesis of complex (3) 
 
O
O
N
N
O
O
HN
N
O
O O
NH
O
Gd
H
O H
N N
N N
Bz Bz
OCH2OCH3H3COH2CO
3  
Following the same procedure adopted for the synthesis of complex 2, 
condensation of ligand 27 (0.15 g, 0.14 mmol) with GdCl3 ● 6H2O afforded complex 3 
as light purple amorphous solid (0.14 g, 82%). m.p. > 300 oC. IR (KBr): 3480, 3042, 
2914, 1631, 1437, 1322, 1245, 1153, 1090 cm-1. Anal. Calcd for C52H62GdN9O14 ● 
4H2O: C, 49.32; H, 5.57; and N, 9.95. Found: C, 49.25; H, 5.64; and N, 9.88. FAB-MS 
(m/z): calcd for C52H62GdN9O14, 1194.37 ([MH]
+). Found: 1194.3 ([MH]+). 
 
4.3.17. Synthesis of 1-(3-Methoxy-4-nitrophenyl)piperazine (28) 
NO2
OCH3
N
H
N
28  
To a solution of compound 22 (2.08 g, 6.10 mmol) in ethanol (20 ml) was added 
3M KOH solution (20.33 ml, 61.0 mmol) and mixture was left stirring for 8 hours at 60 
oC. After completion of the reaction, the reaction was cooled to room temperature, 
DCM (30 ml) was added, and the solution was then transferred to a separation funnel. 
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The solution was washed with H2O (10 ml) and the organic layer was collected, dried 
over CaSO4 and evaporated under vacuum to afford 28 as a dark yellow powder (1.09 
g, 75.31%). MP: 126-129 oC. IR (KBr): 3429, 3339, 2833, 1908, 1606, 1575, 1509, 
1481, 1392, 1335, 1312, 1290, 1250, 1144, 1098, 1019, 972, 817, 747, 655, 612, 571, 
528 cm-1. 1H NMR (500 MHz, CDCl3) δ: 1.95 (br s, 1H), 3.00 (t, 4H, J = 5.19 Hz), 3.36 
(t, 4H, J= 5.21 Hz), 3.93 (s, 3H), 6.30 (s, 1H), 6.39 (dd, 1H, J1 = 10.38 Hz, J2 = 5.19), 
7.93 (d, 1H, J = 9.16 Hz). 13C NMR (125 MHz, CDCl3) δ: 14.27, 45.31, 46.84, 47.68, 
64.74, 96.27, 104.90, 128.12, 128.34, 155.56, 156.02. 
 
4.3.18. Synthesis of 1-(3-(Methoxymethoxy)-4-nitrophenyl) 
piperazine (29) 
NO2
OCH2OCH3
N
H
N
29  
Following the same procedure adopted for the synthesis of compound 28, 
hydrolysis of compound 23 (2.23 g, 6.01 mmol) with 3M KOH afford the title 
compound 29 as a brown paste (1.29 g, 80.39%). IR (KBr): 3429, 2928, 2794, 1898, 
1603, 1552, 1487, 1409, 1333, 1245, 1150, 1095, 1046, 1011, 986, 957, 814, 747, 710, 
620 cm-1. 1H NMR (500 MHz, CDCl3) δ: 2.90 (s, 4H), 3.25 (s, 4H), 3.44 (s, 3H), 5.20 
(s, 2H), 6.37 (d, 1H, J = 9.46 Hz), 6.51 (s, 1H), 7.83 (d, 1H, J = 9.16 Hz). 13C NMR 
(125 MHz, CDCl3) δ: 39.83, 45.32, 47.69, 56.36, 95.29, 100.53, 106.28, 126.79, 
127.99, 129.72, 153.55, 155.39. 
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4.3.19. Synthesis of 3-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-
yl)propanenitrile (30) 
NO2
OCH3
N
N
CN
30  
 
To a solution of compound 28 (1.94 g, 8.2 mmol) in ethanol (30 ml) at 0 oC was 
added triethylamine (2.50 mL, 18.0 mmol) followed by the addition of acrylonitrile 
(1.18 mL, 18.0 mmol). The reaction mixture was stirred for 3 h at 55 oC and then cooled 
to room temperature. The crystallized product was filtered by suction, washed with 
diethyl ether and dried under vacuum to afford 30 as a light yellow powder. Yield: 71%. 
Anal. Calcd for C14H18N4O3: C, 57.92; H, 6.25; and N, 19.30. Found: C, 57.88; H, 6.29; 
and N, 19.22. Melting point: 210-211 oC (decomp). IR (KBr): 3035, 2952, 2250, 1604, 
1569, 1512, 1483, 1446, 1337, 1251, 1236, 1090, 1013 cm-1. 1H NMR (500 MHz, 
CDCl3): δ = 2.57 (t, 2H, J = 6.7 Hz, -CH2CN), 2.67 (br. s, 4H, -CH2NCH2-), 2.76 (t, 
2H, J = 6.7 Hz, -CH2N), 3.42 (br. s, 4H, -CH2NCH2-), 3.95 (s, 3H, -OCH3), 6.33 (d, 
1H, 3.1 Hz, Ar-H), 6.38 (dd, 1H, J = 2.1, 9.2 Hz, Ar-H), 7.96 (d, 1H, J = 9.3 Hz, Ar-
H). 13C NMR (125 MHz, CDCl3): δ = 16.06, 47.03, 52.14, 53.08, 56.20, 97.22, 105.57, 
118.49, 128.75, 129.76, 155.44, 156.21.  
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4.3.20. Synthesis of 3-(4-(3-(Methoxymethoxy)-4-nitrophenyl) 
piperazin-1-yl)propanenitrile (31) 
NO2
OCH2OCH3
N
N
CN
31  
Following the same procedure adopted for the synthesis of 30, the reaction of 
amine 29 with acrylonitrile afforded the title compound 31 as light yellow solid. Yield: 
59%. Anal. Calcd for C15H20N4O4: C, 56.24; H, 6.29; and N, 17.49. Found: C, 56.19; 
H, 6.34; and N, 17.43. Melting point: 215-216 oC (decomp). IR (KBr): 3030, 2962, 
2249, 1605, 1569, 1510, 1483, 1448, 1337, 1253, 1235, 1090, 1013 cm-1. 1H NMR (500 
MHz, CDCl3): δ = 2.49 (t, 2H, J = 6.7 Hz, -CH2CN), 2.58 (m, 4H, -CH2NCH2-), 2.68 
(t, 2H, J = 6.7 Hz, -CH2N), 3.33 (m, 4H, -CH2NCH2-), 3.90 (s, 3H, -OCH3), 5.22 (s, 
2H, -OCH2O-), 6.40 (d, 1H, 3.1 Hz, Ar-H), 6.56 (dd, 1H, J = 2.2, 9.2 Hz, Ar-H), 7.88 
(d, 1H, J = 9.4 Hz, Ar-H). 13C NMR (125 MHz, CDCl3): δ = 16.02, 46.94, 52.11, 53.06, 
56.67, 95.52, 101.21, 106.78, 128.30, 153.77, 155.13. 
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4.3.21. Synthesis of 3-(4-(4-Amino-3-methoxyphenyl)piperazin-
1-yl)propanenitrile (32) 
NH2
OCH3
N
N
CN
32  
Following the same procedure adopted for the synthesis of 17, the reduction of 
the nitro group of compound 30 (1.52 g, 5.24 mmol) afforded the title compound 32 as 
a light purple thick oil. Yield: 88%. Anal. Calcd for C14H20N4O: C, 64.59; H, 7.74; and 
N, 21.52. Found: C, 64.53; H, 7.80; and N, 21.42. IR (KBr): 3407, 3303, 3013, 2940, 
2248, 1592, 1515, 1449, 1424, 1377, 1341, 1139, 1098, 1033 cm-1. 1H NMR (500 MHz, 
CDCl3): δ = 2.49 (t, 2H, J = 7.0 Hz, -CH2CN), 2.62 (t, 4H, J = 5.0 Hz, -CH2NCH2-), 
2.69 (t, 2H, J = 7.0 Hz, -CH2N), 3.02 (t, 4H, J = 5.0 Hz, -CH2NCH2-), 3.51 (br. s, 2H, 
NH2), 3.83 (s, 3H, -OCH3), 6.36 (dd, 1H, J = 2.4, 8.2 Hz, Ar-H), 6.46 (d, 1H, J = 2.4 
Hz, Ar-H), 6.60 (d, 1H, J = 8.2 Hz, Ar-H). 13C NMR (125 MHz, CDCl3) δ: 15.38, 50.68, 
52.40, 52.87, 55.11, 102.00, 109.19, 115.09, 118.54, 130.17, 144.20, 147.61, 165.47. 
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4.3.22. Synthesis of 3-(4-(4-amino-3-(methoxymethoxy)phenyl) 
piperazin-1-yl)propanenitrile (33) 
NH2
OCH2OCH3
N
N
CN
33  
Following the same procedure adopted for the synthesis of 17, the reduction of 
the nitro group of nitrile 31 afforded compound 33 as a light brown oil. Yield: 84%.  
Anal. Calcd for C15H22N4O2: C, 62.05; H, 7.64; and N, 19.30. Found: C, 62.00; H, 7.69; 
and N, 19.24. IR (KBr): 3443, 3359, 2949, 2249, 1591, 1517, 1454, 1378, 1337, 1241, 
1215, 1174, 1075 cm-1. 1H NMR (500 MHz, CDCl3): δ = 2.46 (t, 2H, J = 6.7 Hz, -
CH2CN), 2.59 (br. s, 4H, -CH2NCH2-), 2.68 (t, 2H, J = 6.7 Hz, -CH2N), 2.99 (br. s, 4H, 
-CH2NCH2-), 3.42 (s, 3H, -OCH3), 4.54 (br. s, 2H, NH2), 6.38 (dd, 1H, 2.4, 8.2 Hz, Ar-
H), 6.59 (d, 1H, J = 8.2 Hz, Ar-H), 6.68 (d, 1H, J = 2.3 Hz, Ar-H). 13C NMR (125 MHz, 
CDCl3): δ = 15.69, 50.70, 52.67, 53.18, 56.02, 95.18, 105.94, 111.09, 115.93, 118.65, 
126.98, 130.66, 144.48, 145.63, 166.77. 
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4.3.23. Synthesis of 2,2'-(2,2'-(carboxymethylazanediyl)bis 
(ethane-2,1-diyl)bis((2-(4-(4-(2-cyanoethyl)piperazin-1-yl)-2-
methoxyphenylamino)-2-oxoethyl)-azanediyl))diacetic acid (34) 
N
NN
HO
O
OH HO
O
O
O
O
NH NH
N N
OCH3OCH3
N N
CN CN
34  
Following the same procedure adopted for the synthesis of 18, condensation of 
compound 32 (0.26 g, 0.76 mmol) with DTPAA afforded compound 34 as a gray 
powder. Yield: 51%. Anal. Calcd for C42H59N11O10: C, 57.46; H, 6.77; and N, 17.55. 
Found: C, 57.39; H, 6.83; and N, 17.47. Melting point: 141-142 oC. IR (KBr): 3462, 
2959, 2836, 2252, 1706, 1664, 1534, 1453, 1420, 1396, 1239, 1202, 1174, 1135, 1090, 
1029 cm-1. 1H NMR (500 MHz, d6-DMSO): δ = 2.55 (m, 4H), 2.62-2.68 (m, 8H), 2.71-
2.81 (m, 12H), 3.02 (m, 8H), 3.21-3.33 (m, 12H), 3.77 (s, 6H, -OCH3), 6.35 (d, 2H, J 
= 8.2 Hz, Ar-H), 6.52 (d, 2H, J = 2.4 Hz, Ar-H), 7.80 (dd, 2H, J = 2.5, 8.2 Hz, Ar-H), 
9.32 (s, 2H). 13C NMR (125 MHz, d-DMSO): δ = 14.98, 30.70, 36.24, 48.70, 52.12, 
52.36, 52.72, 54.81, 55.48, 55.69, 59.05, 99.95, 106.85, 120.06, 148.23, 149.66, 162.37, 
168.40, 171.61, 172.40. 
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4.3.24. Synthesis of 2,2'-(2,2'-(carboxymethylazanediyl)bis 
(ethane-2,1-diyl)bis((2-(4-(4-(2-cyanoethyl)piperazin-1-yl)-2-
(methoxymethoxy)phenylamino)-2-oxoethyl)azanediyl))diacetic 
acid (35) 
 
N
NN
HO
O
OH HO
O
O
O
O
NH NH
N N
OCH2OCH3
N N
CN CN
35
H3COH2CO
 
Following the same procedure adopted for the synthesis of 18, condensation of 
compound 33 with DTPAA afforded compound 35 as a light purple powder. Yield: 
63%. Anal. Calcd for C44H63N11O12: C, 56.34; H, 6.77; and N, 16.43. Found: C, 56.27; 
H, 6.85; and N, 16.36. Melting point: 156-157 oC. IR (KBr): 3503, 2964, 2256, 1729, 
1530, 1396, 1219, 1079 cm-1. 1H NMR (500 MHz, d6-DMSO): δ = 2.55 (m, 4H), 2.65-
2.71 (m, 8H), 2.70-2.87 (m, 12H), 3.05 (m, 8H), 3.33-3.43 (m, 16H), 5.20 (s, 4H, -
OCH2O-), 6.52 (d, 2H, J = 8.1 Hz, Ar-H), 6.68 (d, 2H, J = 2.8 Hz, Ar-H), 7.46 (dd, 2H, 
J = 2.7, 8.1 Hz, Ar-H), 7.92 (s, 2H), 9.42 (s, 2H). 13C NMR (125 MHz, d-DMSO): δ = 
14.96, 30.72, 35.82, 48.62, 51.67, 52.05, 52.40, 52.67, 54.81, 54.98, 55.57, 55.90, 
94.56, 103.09, 108.46, 120.02, 162.36, 168.47, 172.37, 172.60. 
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4.3.25. Synthesis of complex (4) 
O
O
N
N
O
O
HN
N
O
O O
NH
O
Gd
H
O H
N N
N N
CN CN
OCH3H3CO
4  
Following the same procedure adopted for the synthesis of complex 2, 
condensation of ligand 34 (0.100 g, 0.114 mmol) with Gd2O3 (0.021 g, 0.057 mmol) 
afforded complex 4 as a light blue solid. Yield: 89%. Anal. Calcd for C42H56GdN11O10 
● 4H2O: C, 45.68; H, 5.84; and N, 13.95. Found: C, 45.62; H, 5.90; and N, 13.89. FAB-
MS (m/z): calcd for C42H56GdN11O10, 1032.35 ([MH]
+). Found: 1032.35 ([MH]+). 
Melting point: > 300 oC. IR (KBr): 3444, 3030, 2927, 2250, 1611, 1456, 1399, 1323, 
1250, 1204, 1135, 1093 cm-1. 
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4.3.26. Synthesis of complex (5) 
O
O
N
N
O
O
HN
N
O
O O
NH
O
Gd
H
O H
N N
N N
CN CN
OCH2OCH3H3COH2CO
5  
Following the same procedure adopted for the synthesis of complex 2, 
condensation of ligand 35 with Gd2O3 afforded complex 5 as light purple solid. Yield: 
83%. Anal. Calcd for C44H60GdN11O12 ● 4H2O: C, 45.39; H, 5.89; and N, 13.23. Found: 
C, 45.32; H, 5.95; and N, 13.26. FAB-MS (m/z): calcd for C44H60GdN11O12, 1092.37 
([MH]+). Found: 1092.37 ([MH]+). Melting point: > 300 oC. IR (KBr): 3486, 3012, 
2845, 2253, 1616, 1403, 1322, 1246, 1123, 1090, 990 cm-1. 
 
4.4. X-ray Photoelectron Spectroscopy 
The experiment was performed in a Thermos Scientific Escalab 250Xi 
spectrometer equipped with a monochromated Al K (1486.6 eV) x-ray source. A low-
energy electron flood gun was used for surface charge compensation. The spectrometer 
energy was calibrated by fixing Cu 2p3/2, Ag 3d5/2 and Au 4f7/2 peaks at binding energies 
of 932.6, 368.2 and 83.9 eV, respectively [31]. The electron energy analyzer was 
operated in constant pass energy of 30 eV and the electron take off angle was 900. The 
instrumental energy resolution was 0.5 eV with x-ray spot size of 650-m diameter. 
The base pressure in the analysis chamber was 5.01010 mbar. The spectra were 
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referenced with C-C 1s peak at 284.8 eV. Avantage software and OriginLab 9.0 was 
used for all data processing. 
 
4.5. Cytotoxicity Study Assay 
Toxicity for chelates (2-5) was analyzed on adherent 3T3 mouse embryonic 
fibroblastic cells by MTT assay following Mesaik et al. [32] with some modification. 
In brief cells were incubated at 6 × 104 ml−1 concentration in 96 well flat bottom plate 
in 5% CO2 and 37 
◦C for 24 h. After adherence of cells, compounds were added at 
concentration 10 µg/ml for further 48 h incubation. On day 3 tetrazolium dye MTT was 
added. After 4 h of incubation media was removed and organic solvent DMSO was 
added to dissolve insoluble purple formazan. Absorbance was taken at 540 nm using 
spectrophotometer and the % viability of cells was calculated. 
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CHAPTER 5 
CONCLUSION AND FUTURE WORK 
In conclusion, four new Gd(III) complexes 2-5 of the type [Gd(L)H2O]·nH2O 
have been synthesized. Complexes 2 and 3 are water insoluble whereas 4 and 5 are 
water soluble. The relaxivity of 2 and 3 were slightly lower compare to Omniscan®, a 
commercially available MRI contrast agent. The lower relaxivity of 2 and 3 was 
attributed to their lower solubility in water. The water solubility of these complexes 
may be increased by incorporating polar functions in the aromatic ring, which in turn, 
may improve their relaxivity. On the other hand, 4 and 5 gave a higher relaxivity 
compare to Omniscan®. The highest relaxivity of 5, among the synthesized complexes, 
is attributed to the increase in solubility owing to the presence MOM function in the 
aromatic ring. The cytotoxicity studies of these complexes revealed that they are non-
toxic which warrant their potential and physiological suitability as MRI contrast agents. 
For the future work, following studies on these complexes are recommended: 
1. Stability constant determination to know stability of these complexes in the 
human body. Stability in the human body is one of the key factors that should 
be considered in the process of designing drugs and pharmaceuticals. 
2. In vivo toxicity studies to determine the maximum dosage that can be 
administered without causing harm to the patient. 
3. In vivo MRI studies to determine the activity of these complexes under MR 
machine in a living subject such as mice. 
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Appendices 
 
Appendix A (4-fluoro-2-methoxy-1-nitrobenzene): 
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Appendix B (4-fluoro-2-(methoxymethoxy)-1-nitrobenzene): 
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Appendix C (4-(4-benzoylpiperazin-1-yl)-2-nitrobenzonitrile): 
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Appendix D (4-(3-methoxy-4-nitrophenyl)piperazin-1-yl)(phenyl)methanone): 
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Appendix E (4-(3-(methoxymethoxy)-4-nitrophenyl)piperazin-1-
yl)(phenyl)methanone): 
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Appendix F (1-(3-methoxy-4-nitrophenyl)piperazine): 
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Appendix G (1-(3-(methoxymethoxy)-4-nitrophenyl)piperazine): 
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Appendix H (1-(3-(methoxymethoxy)-4-nitrophenyl)piperazine): 
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Appendix I (3-(4-(3-(methoxymethoxy)-4-nitrophenyl)piperazin-1-
yl)propanenitrile): 
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Appendix J (2-amino-4-(4-benzoylpiperazin-1-yl)benzonitrile): 
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Appendix K ((4-(4-amino-3-methoxyphenyl)piperazin-1-yl)(phenyl)methanone): 
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Appendix L ((4-(4-amino-3-(methoxymethoxy)phenyl)piperazin-1-
yl)(phenyl)methanone): 
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Appendix M (3-(4-(4-amino-3-methoxyphenyl)piperazin-1-yl)propanenitrile): 
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Appendix N (3-(4-(4-amino-3-(methoxymethoxy)phenyl)piperazin-1-
yl)propanenitrile): 
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Appendix O (2,2'-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis((2-((5-(4-
benzoylpiperazin-1-yl)-2-cyanophenyl)amino)-2-oxoethyl)azanediyl))diacetic 
acid): 
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Appendix P (2,2'-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis((2-((4-(4-
benzoylpiperazin-1-yl)-2-methoxyphenyl)amino)-2-oxoethyl)azanediyl))diacetic 
acid): 
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
Appendix Q (2,2'-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis((2-((4-(4-
benzoylpiperazin-1-yl)-2-(methoxymethoxy)phenyl)amino)-2-
oxoethyl)azanediyl))diacetic acid): 
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Appendix R (2,2'-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis((2-((4-(4-
(2-cyanoethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-2-
oxoethyl)azanediyl))diacetic acid): 
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Appendix S (2,2'-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis((2-((4-(4-
benzoylpiperazin-1-yl)-2-(methoxymethoxy)phenyl)amino)-2-
oxoethyl)azanediyl))diacetic acid): 
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Appendix T (Chelate 2): 
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Appendix U (Chelate 3): 
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Appendix V (Chelate 4): 
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Appendix W (Chelate 5): 
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